Drug Eluting Stents Market By Product (Polymer-Based, Polymer-Free), Application (Coronary Diseases, Peripheral Vascular Diseases), End-User (Hospitals, Ambulatory Surgical Centers, Cardiology Centers), & Region for 2024-2031

Drug Eluting Stents Market Valuation – 2024-2031

The increasing prevalence of cardiovascular diseases, spurred by aging populations, sedentary lifestyles, and rising rates of obesity and diabetes. Furthermore, the rising desire for minimally invasive procedures, which have shorter recovery times and lower risks than standard surgeries, is driving market growth. Favorable reimbursement policies and increasing healthcare spending in emerging markets are driving up the adoption of drug-eluting stents is propelling the market growth surpassing USD 6.27 Billion in 2023 and reaching USD 14.14 Billion by 2031.

Advances in stent technology, such as greater biocompatibility, more effective drug delivery systems, and lower restenosis rates, have considerably improved patient outcomes and boosted drug-eluting stent use. These technological advancements propel market expansion by improving treatment choices for cardiovascular disorders, resulting in increased demand and widespread adoption of minimally invasive procedures.is expected to grow at a CAGR of about 10.71% from 2024 to 2031.

Drug Eluting Stents MarketDefinition/ Overview

Drug-eluting stents (DES) are specialized coronary stents that release medication over time to prevent artery re-narrowing (restenosis) after stent insertion. They are generally used to treat coronary artery disease, keeping blood vessels open and lowering the risk of heart attacks. DES are used in angioplasty treatments to maintain vascular patency and improve patients’ long-term results. The future of drug-eluting stents seems optimistic, with current research focusing on creating better materials, enhanced drug coatings, and new designs to reduce problems and increase effectiveness. Furthermore, the increasing use of DES in peripheral artery disease and other vascular disorders, together with the increased use of minimally invasive cardiovascular operations, is projected to promote continuous growth and innovation in this market.

Will Increasing Prevalence of Cardiovascular Diseases Drive the Drug Eluting Stents Market?

The rising prevalence of cardiovascular diseases (CVDs) is likely to propel the drug-eluting stents (DES) industry. Cardiovascular diseases, including coronary artery disease, remain the major cause of death worldwide. Aging populations, sedentary lifestyles, bad diets, and rising obesity and diabetes rates all contribute to an increase in the prevalence of these disorders. As the number of people with CVDs grows, so will the demand for effective treatment options such as drug-eluting stents.

Drug-eluting stents play an important role in the treatment of coronary artery disease because they keep arteries open and release medication to prevent restenosis. DES are favored over regular bare-metal stents due to their effectiveness in decreasing the recurrence of arterial blockages. With an increasing number of patients requiring angioplasty and other minimally invasive treatments, the use of DES is expected to rise. Advances in stent technology, such as enhanced biocompatibility and medication delivery systems, increase its appeal, resulting in increased clinical use.

Furthermore, the healthcare industry is seeing a shift toward minimally invasive operations, motivated by the advantages of shorter recovery periods, shorter hospital stays, and lower overall costs as compared to traditional surgical interventions. As a result, interventional cardiologists and healthcare professionals are increasingly including drug-eluting stents in their treatment plans. The combination of technology developments and a demand for minimally invasive procedures is projected to drive growth in the DES market.

Favorable reimbursement policies and rising healthcare spending, particularly in emerging nations, are expected to fuel the growth of the drug-eluting stents market. Governments and healthcare organizations are investing in cardiovascular care infrastructure and increasing patient access to sophisticated treatments. This, together with increased awareness about the benefits of early intervention in CVD management, is projected to promote demand for drug-eluting stents. As the global frequency of cardiovascular illnesses rises, the drug-eluting stent industry is positioned for continued expansion and innovation.

Advances in stent technology, such as greater biocompatibility, more effective drug delivery systems, and lower restenosis rates, have considerably improved patient outcomes and boosted drug-eluting stent use. These technological advancements propel market expansion by improving treatment choices for cardiovascular disorders, resulting in increased demand and widespread adoption of minimally invasive procedures.

Will Rising High Cost of Advanced Stent Technologies Hinder the Growth of the Drug Eluting Stents Market?

The rising expense of improved stent technologies is a significant factor that may limit the growth of the drug-eluting stents (DES) industry. Drug-eluting stents, which release medication to prevent arteries from re-narrowing, have advanced dramatically in recent years, leading to better patient outcomes. However, these technological developments result in higher research and development (R&D) expenditures, which are then reflected in the market prices of these gadgets. High costs can limit access to these stents, especially in low- and middle-income countries where healthcare budgets are limited and patients frequently pay a major percentage of their own healthcare costs.

The fiscal burden of pricey DES on healthcare systems and patients may hinder market growth. To meet budget constraints, healthcare professionals may choose less expensive options such as bare-metal stents or even older-generation DES. This cost-conscious decision-making process may diminish overall demand for newer, more expensive DES. Furthermore, insurance companies and government health programs may impose stricter reimbursement policies, limiting coverage for expensive stents unless absolutely essential. This will further restrict patient access to improved DES, limiting market growth.

Furthermore, the cost element can impact the competitive landscape of the DES industry. Smaller enterprises and new entrants may struggle to compete with established competitors who have larger R&D expenditures and can bear higher costs. Financial hurdles hinder smaller companies from investing in the development of sophisticated stent technologies, which can lead to less innovation and fewer new goods entering the market. Reduced competition can also lead to market consolidation, with a few major corporations dominating, potentially resulting in higher pricing and fewer options for healthcare providers and patients.

The drug-eluting stent (DES) market faces considerable challenges, such as expensive development and production costs and demanding regulatory approvals. Intense rivalry and the ongoing demand for innovation add to financial strains. Furthermore, high costs and limited healthcare infrastructure restrict access in underdeveloped countries, impeding market expansion. The possibility of undesirable consequences such as late stent thrombosis, as well as the introduction of alternative treatments like as bioresorbable stents and drug-coated balloons, all provide additional challenges to market stability.

Category-Wise Acumens

Will Increasing Demand for Polymer-Based Stents Drive the Drug Eluting Stents Market?

The growing demand for polymer-based drug-eluting stents (DES) is expected to boost the total drug-eluting stent market. Polymer-based DES have gained popularity in the market due to their ability to release medication over time. This controlled drug release helps to prevent restenosis, which is a major problem with bare-metal stents. Also, advances in polymer-based stent technology have resulted in increased biocompatibility and safety, making them more appealing to healthcare practitioners and patients. The stents’ dependability and constant performance continue to drive their use, particularly in healthcare systems where patient outcomes and high-quality care are critical.

The popularity of polymer-based stents can be related to their capacity to offer localized and prolonged medication release, which can improve patient outcomes and lower the likelihood of problems. This trait has resulted in a growing preference for these stents in clinical practice, particularly among patients with severe coronary artery disease who require advanced treatment approaches. The effectiveness of polymer-based stents in lowering the risk of restenosis and facilitating speedier recovery has made them a popular choice among healthcare practitioners, fueling total market demand.

Furthermore, the rising frequency of cardiovascular illnesses and an aging population in different regions, particularly North America and Europe, have increased the demand for sophisticated treatment options such as polymer-based drug-eluting stents. These stents provide a safer and more effective way to treat arterial blockages and improve patient outcomes. With increased awareness and acceptance of minimally invasive procedures, healthcare providers are increasingly turning to drug-eluting stents, particularly those with polymer coatings, to provide optimal patient recovery and care.

However, the polymer-free stents category is growing the fastest as medical technology advances and there is a greater desire for more targeted and efficient therapeutic choices. Polymer-free stents provide a distinct advantage by removing the risks associated with polymer coatings, such as late-stent thrombosis and allergic responses. This breakthrough establishes polymer-free DESs as a promising alternative, especially as healthcare practitioners and patients prefer sophisticated, minimally invasive therapies with fewer consequences. As a result, the polymer-free category is gaining pace and is likely to contribute significantly to total market growth.

Will Rising Usage of Hospitals Drive the Drug Eluting Stents Market?

The increasing use of hospitals is expected to drive the drug-eluting stents (DES) industry significantly. Hospitals, being comprehensive healthcare facilities, play an important role in the adoption of sophisticated medical technology like DES. With the rising frequency of cardiovascular illness, hospitals are undertaking more sophisticated cardiac surgeries that require the use of drug-eluting stents to achieve best patient outcomes. The rising patient population and the requirement for high-quality care in these settings drive up the need for improved therapeutic methods.

Furthermore, hospitals provide a wide range of specialist services, such as interventional cardiology procedures that require drug-eluting stents to treat ailments like coronary artery disease. Hospitals’ improved infrastructure and availability of competent healthcare workers make drug-eluting stents easier to utilize, ensuring that patients receive efficient and successful therapy. Furthermore, the growing emphasis on minimally invasive procedures that encourage faster recovery periods and lower problems is driving the use of drug-eluting stents in hospitals.

The growing use of hospitals is also affected by increasing awareness among healthcare practitioners and patients of the benefits of drug-eluting stents in avoiding restenosis and enhancing long-term artery health. Hospitals, with their entire healthcare ecosystem, can provide a greater range of treatment options and better diagnostic tools, resulting in increasing drug-eluting stent use. This increase in hospital utilization creates a favorable environment for the growth of the drug-eluting stents market.

However, ambulatory surgical centers (ASCs) are the fastest expanding segment. ASCs are gaining popularity due to their emphasis on cost-effective, outpatient operations with shorter recovery times, attracting a larger patient base for minimally invasive cardiac therapies. The efficiency and streamlined approach of ASCs is pushing the adoption of drug-eluting stents in these settings, resulting in their rapid market growth.

Gain Access into Drug Eluting Stents Market Report Methodology

Country/Region Wise Acumens

Will Rise in Adoption of Advanced Medical Technology in North America Drive the Drug Eluting Stents Market?

The adoption of modern medical technologies in North America is expected to drive the drug-eluting stent (DES) industry. One of the key drivers of this trend is the rising prevalence of cardiovascular illnesses (CVDs), necessitating improved treatment options such as DES. As medical technology advances, these devices provide superior outcomes in terms of lower restenosis rates and faster patient recovery times than standard bare-metal stents. The growing desire for minimally invasive procedures accelerates the adoption of drug-eluting stents, which provide less invasive choices for treating artery blockages.

North America also houses some of the world’s biggest medical device manufacturers and healthcare facilities, which invest extensively in research and development (R&D). These investments help to drive the ongoing evolution and improvement of drug-eluting stent technology, making them more efficient and safer for patients. The increased awareness among healthcare professionals and patients regarding the advantages of DES over alternative therapies is also a motivator. As North American healthcare institutions continue to focus patient outcomes, there is a strong drive to adopt cutting-edge medical therapies.

Furthermore, advantageous reimbursement policies and healthcare infrastructure in North America promote the use of innovative medical devices, such as drug-eluting stents. Health insurers and government programs frequently subsidize the expenses of such advanced medical therapies, encouraging greater acceptance and use by the patient population. This, together with the availability of qualified medical professionals capable of performing complex procedures with these modern technologies, will help to drive the expansion of the drug-eluting stent market.

The vast and expanding patient population with cardiovascular diseases in North America is critical to boosting the drug-eluting stents industry. As the frequency of cardiac disease increases, so does the demand for advanced, minimally invasive treatment options such as DES. This high prevalence of cardiovascular problems provides a consistent patient base seeking improved therapeutic solutions, creating a favorable environment for industry growth and innovation.

Will Increasing Healthcare Expenditure in Asia-Pacific Propel the Drug Eluting Stents Market?

Increasing healthcare expenditure in the Asia-Pacific region is expected to significantly boost the drug-eluting stents (DES) market due to a number of linked reasons, increasing healthcare spending in nations such as China, India, and Japan result in improved healthcare infrastructure and access to innovative medical technologies. Governments and the business sector are investing more in healthcare, increasing the capacity to adopt novel treatments such as DES. This boost in funding helps hospitals and clinics purchase necessary equipment and train healthcare personnel, increasing the use of DES in the treatment of coronary artery disease.

The growing middle class and greater awareness of health issues in Asia-Pacific lead to increased demand for modern medical treatments. With rising disposable money, more people can afford better healthcare, which leads to an increase in elective operations like DES. Furthermore, health awareness efforts and educational initiatives on heart disease and its therapies urge individuals to seek sophisticated treatment options like as DES. This social change toward valuing health and well-being has a direct impact on market growth, increasing demand for sophisticated medical gadgets.

The Asia-Pacific area is experiencing an increase in the prevalence of cardiovascular diseases (CVD), which is being driven by urbanization, lifestyle changes, and aging populations. As CVD becomes increasingly widespread, the demand for effective treatment options such as DES grows. Drug-eluting stents, which release medication to avoid arterial blockage, are very useful in controlling coronary artery disease. As a result, the growing burden of CVD necessitates the use of modern medical technologies, such as DES, to improve patient outcomes while also lowering long-term healthcare costs by reducing the need for recurrent surgeries.

Governments and commercial sectors in Asia-Pacific are dramatically boosting their healthcare investments, improving access to innovative medical technologies and treatments. This influx of funding helps to modernize hospital infrastructure, makes it easier to acquire cutting-edge medical technologies such as drug-eluting stents (DES), and assures better training for healthcare workers. As a result, patients benefit from improved treatment options and outcomes, which drives the regional DES market.

Competitive Landscape

The competitive landscape of the drug-eluting stents market is characterized by intense competition and innovation, driven by the increasing prevalence of cardiovascular diseases and the demand for minimally invasive procedures. Companies in this market are focusing on developing next-generation stents with enhanced biocompatibility, improved drug delivery systems, and reduced restenosis rates. Additionally, there is a significant emphasis on conducting clinical trials to demonstrate the safety and efficacy of new products. Emerging players are entering the market with novel technologies, while established firms are expanding their portfolios through mergers, acquisitions, and collaborations. The market is also witnessing geographic expansion as companies target emerging markets with high patient populations and growing healthcare infrastructure. Competitive pricing, product differentiation, and strategic partnerships are key strategies employed by companies to gain a competitive edge in the drug-eluting stents market.

Some of the prominent players operating in the drug eluting stents market include

Boston Scientific Corporation, MicroPort Scientific Corporation, Terumo Corporation, Biosensors International Group Ltd., Abbott, Medtronic, Biotronik, Medinol Ltd., Coo, STENTYS SA.

Latest Developments

• In March 2024, Boston Scientific Corporation (NYSEBSX) has gained FDA approval for the AGENT™ Drug-Coated Balloon (DCB), recommended for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is defined as the obstruction or narrowing of a stented artery caused by plaque or scar tissue.
• In December 2023, Terumo India introduces Ultimaster Nagomi, a drug-eluting stent appropriate for both small and large coronary arteries. This allows for customized stent selection for a wider patient population.

Report Scope

Drug Eluting Stents Market, By Category

Product

• Polymer-Based
• Polymer-Free

Application

• Coronary Diseases
• Peripheral Vascular Diseases

End-User

• Hospitals
• Ambulatory Surgical Centers
• Cardiology Centers

Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Research Methodology of Market Research